AstraZeneca: advances head and neck cancer drug to Phase III
(CercleFinance.com) - AstraZeneca has decided that it will advance Innate Pharma's monalizumab into Phase III trial for treatment of head and neck cancer.
The randomized clinical trial will evaluate monalizumab, in combination with Merck's cetuximab, in patients suffering from recurrent or metastatic squamous cell carcinoma of the head and neck, the two partners said.
AstraZeneca and Innate Pharma will jointly fund the trial, which is expected to start in 2020.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The randomized clinical trial will evaluate monalizumab, in combination with Merck's cetuximab, in patients suffering from recurrent or metastatic squamous cell carcinoma of the head and neck, the two partners said.
AstraZeneca and Innate Pharma will jointly fund the trial, which is expected to start in 2020.
Copyright (c) 2019 CercleFinance.com. All rights reserved.